CAPRICOR THERAPEUTICS, INC. Property, Plant and Equipment, Gross
CAPRICOR THERAPEUTICS, INC. (CAPR) had Property, Plant and Equipment, Gross of $42.49 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-08-14
- 2026-06-30: Property, Plant and Equipment, Gross $42.49M.
- 2026-03-31: Property, Plant and Equipment, Gross $34.15M.
- 2025-12-31: Property, Plant and Equipment, Gross $23.46M.
- 2025-09-30: Property, Plant and Equipment, Gross $15.72M.
| Period end | Property, Plant and Equipment, Gross | Property, Plant and Equipment, Gross as first filed |
|---|---|---|
| 2026-06-30 | $42.49M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $34.15M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $23.46M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $15.72M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $12.15M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $9.81M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $9.01M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $8.56M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $8.50M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $8.42M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $7.77M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $7.04M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $6.44M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $6.21M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $5.77M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $4.67M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $3.57M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $3.16M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $2.55M 10-K · filed 2023-03-17 | |
| 2021-09-30 | $2.40M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.93M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $1.61M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $1.57M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $1.28M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $1.13M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $1.02M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $1.02M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $1.02M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $1.02M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $1.03M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $1.03M 10-K · filed 2020-03-27 | |
| 2018-09-30 | $1.05M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $900.37K 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $900.13K 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $713.75K 10-K · filed 2019-03-29 | |
| 2017-09-30 | $713.75K 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $697.40K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $689.14K 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $686.01K 10-K · filed 2018-03-22 | |
| 2016-09-30 | $580.47K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $569.71K 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $538.08K 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $492.27K 10-K · filed 2017-03-16 | |
| 2014-12-31 | $341.05K 10-K · filed 2016-03-30 | |
| 2014-09-30 | $325.05K 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $294.82K 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $247.52K 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $154.62K 10-K · filed 2015-03-16 | |
| 2012-12-31 | $98.50K 10-K · filed 2014-03-31 | $50.35K 10-K · filed 2013-06-21 |
| 2011-12-31 | $50.35K 10-K · filed 2013-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |